Sign In

Christie Assure Program Expands to More Than 40 Countries Revolutionizing VeinViewer Training for Hospitals and Physician Offices

Publication Date: 8/26/2013

​MEMPHIS, Tenn. – (AUGUST 26, 2013) – Christie Medical Holdings, Inc., today announced the expansion of its industry-leading program to more than 40 countries. The Christie Assure Program will be offered to acute hospitals and physician offices that use the HD VeinViewer® vein illumination products designed to project vascular imaging on the surface of the skin.

The Christie Assure Program is a five-year comprehensive set of services which include warranty, access to online clinical education and an upgrade program to the latest Christie product platforms.  An industry-first, the Christie Assure Program represents a significant leadership investment in seeing the end customer achieve utilization and results through Christie technologies.​


Chris Schnee, general manager and vice president of sales and marketing at Christie Medical Holdings, said, “We launched VeinViewer GS (global standard) internationally in 2008. Today we have three leading products, the 3rd, 4th and 5th generation VeinViewers, being sold around the world. Through our technology leadership, and unmatched support and education for hospital staff and physician offices we aim to help VeinViewer users achieve an increase in patient satisfaction, potential reduction in patient risk and infection, and maximize health care economic benefits at their hospitals and offices.”

The Christie Assure Program was built upon the results of a thorough Voice of Customer survey that addressed customer priorities. Customers told Christie they wanted the company to help them achieve the same results demonstrated in multiple clinical studies, which have proven the benefits of VeinViewer technology. Results show up to a 100 percent increase in first stick success rates, up to a 100 percent increase in patient satisfaction ratings and a 50 percent decrease in medically unnecessary PICC lines. The goal is to maximize the positive return each facility receives from its investment and to improve patient care.

Customers also wanted to have the confidence that the company standing behind the technology is committed for the long term. Schnee continued: “Through Christie Assure, we achieve one of the highest levels of customer support; higher than any I have seen in my career.”

Customers should review the Christie Assure Program in detail for relevant terms that apply.

Recently, the company’s three clinical studies encompassing 3,000 data points, compared VeinViewer’s measurements to that of ultrasound, the industry gold standard. The studies, vetted and approved by Institutional Review Board (IRB) Services, demonstrated that VeinViewer measured accurate within half a millimeter on average, and for veins most commonly accessed for a peripheral IV (3mm-7mm wide), it projected near perfect vein widths (+/- 0.06mm).

VeinViewer Validated in Ten Published Clinical Peer Reviews
VeinViewer has undergone ten stringent peer reviews since 2006, nine published within the last two-and-a-half years.  Third-party medical peer reviews demonstrate the statistically significant clinical effectiveness of VeinViewer, and often also include an evaluation of its potential savings, demonstrating not only clinical benefits, but positive impact to the bottom line.

VeinViewer Technology Backed by Christie’s Long History of Technical Achievements
VeinViewer technology was developed with the aid of the engineering capabilities and resources of parent company Christie Digital Systems, a leading global visual technology firm with more than 80 years of experience in the projection systems industry. VeinViewer is the first and only device on the market to use: harmless near-infrared light, DLP® technologies, exclusive technology such as Active Vascular Imaging Navigation (AVIN™) providing the demanded Pre, During and Post-access (PDP) benefits, TrueView imaging accuracy in projected vein-widths which is three to ten times more accurate than competition, and technologies such as Df2 (Digital full field) to illuminate the only real-time HD digital image of subcutaneous vasculature and blood patterns directly onto the skin surface . Although designed for assistance in IV starts and blood draws, VeinViewer has proven beneficial in spider and varicose vein treatment.

To learn more about Christie product offerings: 3rd generation VeinViewer Vision, 4th generation VeinViewer VisionXTND and 5th generation VeinViewer Flex, please visit www.veinviewer.com.

About Christie Medical Holdings, Inc.
Christie Medical Holdings Inc. is a global company based in Memphis, Tenn., that discovers, develops and commercializes medical technologies. The company’s market-leading product, VeinViewer, is a mobile vascular imaging system that allows health care providers to clearly see accessible vasculature as a real time HD image, directly on the surface of the skin. Christie Medical Holdings Inc. is owned by Christie Digital Systems Inc., a global visual technologies company and a subsidiary of Ushio Inc., Japan (JP:6925). For more information on Christie Digital Systems or Christie Medical Holdings, visit www.christiedigital.com

Christie® is a trademark of Christie Digital Systems USA, Inc., registered in the United States of America and certain other countries.
DLP® is a registered trademark of Texas Instruments.